Table 2

Individual study results for all outcomes of interest in the NMA

ARR at 24 months (ARR ratio, 95% CI)3-month confirmed disability progression at 24 months (HR, 95% CI)6-month confirmed disability progression at 24 months (HR, 95% CI)
Highly active RRMS
 Subgroup analysis of FREEDOMS and FREEDOMS II200.52 (0.40 to 0.69)0.66 (0.45 to 0.96)NA
 EPAR DMF180.57 (0.39 to 0.84)1.19 (0.66 to 2.15)NA
Rapidly evolving severe RRMS
 Subgroup analysis of FREEDOMS and FREEDOMS II230.43 (0.25 to 0.77)0.76 (0.30 to 1.92)0.67 (0.22 to 2.00)
 Subgroup analysis of AFFIRM24 250.25 (0.16 to 0.39)0.47 (0.24 to 0.93)0.36 (0.17 to 0.76)
  • NMA not feasible for this outcome.

  • ARR, annualised relapse rate; DMF, dimethyl fumarate; EPAR, European Public Assessment Report; NA, not applicable; NMA, network meta-analysis; RRMS, relapsing–remitting multiple sclerosis.